AlloSCOPETM Platform
Enabling commercially viable, next-generation cell therapies
AlloSCOPETM (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) is the name we’ve given to our proprietary allogeneic cell manufacturing platform. AlloSCOPE describes a proprietary differentiation and production modality from which we have demonstrated the ability to manufacture allogeneic, cell-based products derived from a single initial cell line, conferring consistent, cost-effective, and scalable cell-based production.
From our AlloSCOPE platform, we develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body.
The cells we manufacture are produced by applying directed differentiation processes to established, well-characterized, and self-renewing pluripotent cell lines. These processes are based on specific developmental lineages and generate cells with desired characteristics. Functional cells developed from such lineages, and which are relevant to the underlying condition, are transplanted into patients in an effort to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or enhance the patient’s functional activity in that target tissue.
- Pluripotent stem cell lines (PSCs) provide an endless supply of starting material
- PSCs can become each of the 200+ cell types of the human body
- No genetic editing is required, but can be included
- The target cell has been validated by evolution
- Residual pluripotent cells are undetectable
- Ready to inject formulation (no dose preparation delay)
- One-time treatment – cells integrate without rejection
- Scalable process for clinical and commercial use